Berger Karin, Ehlken Birgit, Kugland Barbara, Augustin Matthias
MERG, Forschungsgruppe Medizinische Okonomie.
J Dtsch Dermatol Ges. 2005 Jul;3(7):511-8. doi: 10.1111/j.1610-0387.2005.05729.x.
Data regarding costs of outpatient and office-based care, as well as out-of-pocket expenses, for psoriasis patients in Germany are not available. Aim of this study was to assess average annual cost and cost per flare of outpatient and office-based care for patients with moderate to severe chronic psoriasis vulgaris from several perspectives.
In this multi-center, cross-sectional, retrospective and prospective cost-of-illness study, direct (medical and non-medical) and indirect costs were considered from patient, third-party payer (TPP) and societal perspectives.
Out of 227 patients enrolled consecutively in 17 centers, 192 cases could be analyzed. On average, TPP reimbursed 864 per patient annually, 60 % for prescribed medication and 22 % for hospitalization. Patients spent 596 yearly mainly for alternative therapies and OTC-medication/skin care products as well as for additional expenses (e. g. ultraviolet lamp, clothes or cleaning agents). Indirect costs per patient amounted to 1,440 yearly. Total annual costs per patient were 2,866 and 4,985 if treated with systemic drugs additionally. 1,173 if treated topically and/or with phototherapy.
The relatively high average annual costs per patient indicate need for efficient control of psoriasis. This cost-of-illness study provides basic data for further decision making, including economic assessment of innovative therapies for psoriasis.
德国银屑病患者门诊及诊所护理费用以及自付费用的数据尚不可得。本研究旨在从多个角度评估中重度慢性寻常型银屑病患者门诊及诊所护理的年均成本及每次发作的成本。
在这项多中心、横断面、回顾性和前瞻性疾病成本研究中，从患者、第三方支付者（TPP）和社会角度考虑了直接（医疗和非医疗）成本和间接成本。
在17个中心连续招募的227例患者中，192例可进行分析。平均而言，TPP每年为每位患者报销864欧元，其中60%用于处方药，22%用于住院治疗。患者每年花费596欧元，主要用于替代疗法、非处方药/皮肤护理产品以及额外费用（如紫外线灯、衣物或清洁剂）。每位患者的间接成本每年达1440欧元。若额外使用全身药物治疗，每位患者每年的总成本为2866欧元；若采用局部治疗和/或光疗，总成本为4985欧元；若采用局部治疗，总成本为1173欧元。
每位患者相对较高的年均成本表明需要有效控制银屑病。这项疾病成本研究为进一步决策提供了基础数据，包括对银屑病创新疗法的经济评估。
